Who invested in Nurix Therapeutics

One round we have observed, with the 6 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$250Mraised across 1 round since 2025, from 1 source

Latest round: Round, $250MOct 2025
Investors: 6

See who backed them

The rounds

Oct 2025
Round$250M
Source recorded

Founders and team

From Nurix Therapeutics's own website and the SEC filings it signed: 9 on the team.

John NorthcottChief Commercial Officer
Wes BurwellChief Human Resources Officer
Hans van HouteChief Financial Officer
Anil KapurBoard Director
Edward C. SaltzmanBoard Director
Paul M. SilvaBoard Director
Arthur SandsExecutive Officer, Directori
Christine RingExecutive Officeri
Julia P. GregoryChair

On the board, as filediDavid LaceyJeff TongLeon ChenLori KunkelRobert Tjian

Everyone who backed them

Wellington ManagementVC firm1round

General AtlanticPrivate equity1round

Perceptive AdvisorsAsset manager1round

Redmile GroupVC firm1round

Foresite CapitalPrivate equity1round

Bain Capital Life SciencesPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Nurix Therapeutics

Who invested in Nurix Therapeutics?

Nurix Therapeutics's investors include Wellington Management, General Atlantic, Perceptive Advisors, Redmile Group and Foresite Capital, and 1 more on record.